Scotland Approves Novartis / ThromboGenics’ Jetrea and Roche’s RoActemra

The Scottish Medicines Consortium (SMC) has announced their latest set of recommendations approving regulatory submissions for Novartis and ThromboGenics’ eye therapy Jetrea and Roche’s RoActemra. The SMC have also announced rejections for the chronic obstructive pulmonary disease (COPD) drugs submitted for approval by Boehringer Ingelheim and GlaxoSmithKline (GSK).

Continue Reading

European Regulators Grant Boehringer’s Nintedanib Accelarated Assessment

Boehringher Ingelheim have announced the successful marketing authorisation application for nintedanib, and confirmed that Europe’s regulatory body, the European Medicines Agency (EMA), will commence an accelerated assessment of the drug for the treatment of the fatal lung disease idiopathic pulmonary fibrosis (IPF). “IPF is a relentless and fatal lung disease, and there is a high

Continue Reading

NICE Recommends Boehringer’s Cancer Drug, Giotrif

Lung cancer patients in England and Wales could gain access to a new treatment after cost regulators, NICE, have recommended Boehringer Ingelheim’s targeted therapy Giotrif (afatinib). The National Institute for Health and Care Excellence (NICE) has published draft regulatory guidance recommending Giotrif as an option for treating locally advanced or metastatic non-small-cell lung cancer (NSCLC),

Continue Reading

Clinical Professionals act as functional provider for Boehringer Ingelheim – offering CTA roles

We are acting as a functional provider for Boehringer Ingelheim – and therefore we are the only recruitment company offering the Clinical Trial Administrator (CTA) roles. Boehringer Ingelheim is one of the top 20 leading pharmaceutical companies in the world, with 699 of their 46,000 employees from the UK. Working with Boehringer Ingelheim is therefore

Continue Reading

Diabetes Drug, Jentadueto, Reaches UK Market

Patients in the UK with type II diabetes now have access to a new alternative for managing their blood glucose levels with the launch of Boehringer Ingelheim/Eli Lilly’s new combination drug, Jentadueto, being launched in the UK this week. Jentadueto combines two antiglycaemic therapies – the veteran drug metformin with the dipeptidyl peptidase (DPP)-IV inhibitor

Continue Reading

Boehringer Submits Afatinib to EMA

Boehringer Ingelheim announced earlier today that they have submitted their first oncology compound, afatinib, to European regulators. The German firm filed a marketing authorisation application to the European Medicines Agency (EMA) for the approval of afatinib as a treatment for patients with EGFR (ErbB1) mutation positive non-small cell lung cancer (NSCLC).  Boehringer confirmed that afatinib

Continue Reading

Jentadueto Receives European Commission Marketing Authorisation

European regulators have given approval to Boehringer Ingelheim and Eli Lilly’s diabetes combo drug, Jentadueto. The pharmaceutical organisations announced earlier today that they received marketing authorisation from the European Commission (EC) for Jentadueto, which combines metformin with the dipeptidyl peptidase (DPP)-IV inhibitor Trajenta (linagliptin) in a single pill. The approval was expected after the European

Continue Reading

Pradaxa Receives Final Draft OK From NICE

Final draft guidance released from the UK’s National Institute for Health and Clinical Excellence (NICE) recommends the use of Boehringer Ingelheim’s Pradaxa (dabigatran) for the prevention of stroke and systemic embolism in people with atrial fibrillation. In addition, the draft guidance recommends that the decision on whether to start treatment with Pradaxa should be made

Continue Reading

Boehringer Ingelheim and Gilead Sign Agreement for HIV Compound Rights

German corporation, Boehringer Ingelheim, and the Californian firm, Gilead Sciences, have entered into a licensing agreement, under which Boehringer Ingelheim has given Gilead exclusive worldwide rights for the research, development and commercialisation of its novel non-catalytic site integrase inhibitors for HIV. This includes the lead compound BI 224436, which has been evaluated in a Phase

Continue Reading